{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A+or+B+With+Inhibitors",
    "query": {
      "condition": "Hemophilia A or B With Inhibitors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A+or+B+With+Inhibitors&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:13:00.831Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02548143",
      "title": "LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "6 Months to 75 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2016-08-25",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548143"
    },
    {
      "nct_id": "NCT00108758",
      "title": "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "2 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2004-03",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 13,
      "location_summary": "Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108758"
    },
    {
      "nct_id": "NCT01561391",
      "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "factor IX",
          "type": "OTHER"
        },
        {
          "name": "factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561391"
    },
    {
      "nct_id": "NCT03417245",
      "title": "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "fitusiran",
          "type": "DRUG"
        },
        {
          "name": "factor concentrates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2018-03-01",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417245"
    },
    {
      "nct_id": "NCT04489537",
      "title": "Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor",
        "Hemophilia B With Inhibitor"
      ],
      "interventions": [
        {
          "name": "MarzAA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catalyst Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-05-04",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04489537"
    },
    {
      "nct_id": "NCT00002386",
      "title": "Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections",
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Zalcitabine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "16 Years and older · Male only"
      },
      "enrollment_count": 55,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002386"
    },
    {
      "nct_id": "NCT04647227",
      "title": "SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor",
        "Hemophilia B With Inhibitor"
      ],
      "interventions": [
        {
          "name": "coagulation factor VIIa [recombinant]-jncw",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Thrombosis and Hemostasis Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 55,
      "start_date": "2021-06-28",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04647227"
    },
    {
      "nct_id": "NCT02020369",
      "title": "Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A With Inhibitors",
        "Hemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "rEVO Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "12 Years to 75 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2014-04",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020369"
    },
    {
      "nct_id": "NCT03938792",
      "title": "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "PF-06741086",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "74 Years",
        "sex": "MALE",
        "summary": "12 Years to 74 Years · Male only"
      },
      "enrollment_count": 189,
      "start_date": "2020-03-09",
      "completion_date": "2025-04-29",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938792"
    },
    {
      "nct_id": "NCT03417102",
      "title": "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "fitusiran",
          "type": "DRUG"
        },
        {
          "name": "Bypassing agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2018-02-14",
      "completion_date": "2021-06-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-07-24T02:13:00.831Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417102"
    }
  ]
}